Sorafenib tosylate novel drug delivery systems: Implications of nanotechnology in both approved and unapproved indications
Hrushikesh Raut,
Chetana Jadhav,
Karishma Shetty,
Neha Laxane,
Harsh P. Nijhawan,
GSN Koteswara Rao,
Rajasekhar Reddy Alavala,
Garima Joshi,
Ch. Niranjan Patro,
Govind Soni,
Khushwant S. Yadav
Affiliations
Hrushikesh Raut
Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM'S NMIMS (Deemed to be University), Mumbai, India
Chetana Jadhav
Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM'S NMIMS (Deemed to be University), Mumbai, India
Karishma Shetty
Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM'S NMIMS (Deemed to be University), Mumbai, India
Neha Laxane
Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM'S NMIMS (Deemed to be University), Mumbai, India
Harsh P. Nijhawan
Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM'S NMIMS (Deemed to be University), Mumbai, India
GSN Koteswara Rao
Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, Uttar Pradesh, India
Rajasekhar Reddy Alavala
Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM'S NMIMS (Deemed to be University), Mumbai, India
Garima Joshi
Department of Pharmaceutical Sciences, Mohanlal Sukhadia University, Udaipur Rajasthan, India
Ch. Niranjan Patro
Roland Institute of Pharmaceutical Sciences, Khodasingi, Ganjam, Berhampur, Odisha, India
Govind Soni
Oriental College of Pharmacy and Research, Oriental University, Indore, India
Khushwant S. Yadav
Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM'S NMIMS (Deemed to be University), Mumbai, India; Corresponding author.
The USFDA has approved sorafenib tosylate for the treatment of thyroid cancer, kidney cancer, and hepatocellular carcinoma. Conventional formulations of sorafenib tosylate have challenges of solubility, permeability, side effects, and drug resistance across cancer cells. Targeted cancer therapies based on nanotechnology have proven to be effective and have the potential to become a useful tool in these approved cancer indications. In addition, Sorafenib tosylate's novel formulations are also being investigated for the unapproved indications like hepatocellular cancer, renal cancer, and cholangiocarcinoma with promising outcomes. Nanotechnology-based formulations have shown considerable gains in bioavailability, absorption, and increased anticancer efficacy. The article reviews some of the relevant patents and clinical trials in this field. The article also assesses challenges associated and future prospects in designing such clinical ready novel formulations of sorafenib tosylate.
